Hidekazu Itamura

435 total citations
22 papers, 292 citations indexed

About

Hidekazu Itamura is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Hidekazu Itamura has authored 22 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 9 papers in Immunology and 8 papers in Genetics. Recurrent topics in Hidekazu Itamura's work include Hematopoietic Stem Cell Transplantation (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Hidekazu Itamura is often cited by papers focused on Hematopoietic Stem Cell Transplantation (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Hidekazu Itamura collaborates with scholars based in Japan and United States. Hidekazu Itamura's co-authors include Shinya Kimura, Takero Shindo, Jun‐ichi Kadota, Masao Ogata, Shinichi Kako, Takahiro Fukuda, Takashi Yoshida, Toshimitsu Ueki, Hirokazu Okumura and Koji Nagafuji and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Clinical Infectious Diseases.

In The Last Decade

Hidekazu Itamura

22 papers receiving 288 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hidekazu Itamura Japan 8 150 138 94 41 40 22 292
Daniela Vallerini Italy 9 118 0.8× 96 0.7× 52 0.6× 53 1.3× 58 1.4× 15 233
Ryoko Yamasaki Japan 11 116 0.8× 67 0.5× 166 1.8× 18 0.4× 55 1.4× 33 314
Maite Encuentra Spain 9 162 1.1× 59 0.4× 77 0.8× 43 1.0× 84 2.1× 18 326
Evren Özdemir Türkiye 10 134 0.9× 247 1.8× 112 1.2× 32 0.8× 124 3.1× 24 448
Yuichiro Nawa Japan 10 101 0.7× 70 0.5× 145 1.5× 68 1.7× 49 1.2× 32 337
D I Marks United Kingdom 10 61 0.4× 74 0.5× 153 1.6× 46 1.1× 41 1.0× 15 314
Chiara Quadrelli Italy 8 90 0.6× 57 0.4× 40 0.4× 31 0.8× 36 0.9× 13 174
Irene García‐Cadenas Spain 11 198 1.3× 94 0.7× 270 2.9× 32 0.8× 84 2.1× 45 407
Joanne Filicko-O’Hara United States 9 83 0.6× 80 0.6× 189 2.0× 58 1.4× 107 2.7× 48 302
Erik L. Kimble United States 6 106 0.7× 89 0.6× 32 0.3× 24 0.6× 39 1.0× 31 218

Countries citing papers authored by Hidekazu Itamura

Since Specialization
Citations

This map shows the geographic impact of Hidekazu Itamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hidekazu Itamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hidekazu Itamura more than expected).

Fields of papers citing papers by Hidekazu Itamura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hidekazu Itamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hidekazu Itamura. The network helps show where Hidekazu Itamura may publish in the future.

Co-authorship network of co-authors of Hidekazu Itamura

This figure shows the co-authorship network connecting the top 25 collaborators of Hidekazu Itamura. A scholar is included among the top collaborators of Hidekazu Itamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hidekazu Itamura. Hidekazu Itamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Okamoto, Sho, Keita Kai, Hidekazu Itamura, et al.. (2025). Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction. International Journal of Hematology. 122(1). 148–152. 1 indexed citations
2.
Shimada, Kazuyuki, Ken Ohmachi, Ryunosuke Machida, et al.. (2024). Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy – a supplementary analysis of JCOG0601. Annals of Hematology. 103(6). 2021–2031. 2 indexed citations
3.
Ureshino, Hiroshi, Makoto Fukuda, Mariko Miyazaki, et al.. (2023). Type II Cryoglobulinemic Membranoproliferative Glomerulonephritis Caused by Mucosa-associated Lymphoid Tissue Lymphoma. Internal Medicine. 62(13). 1983–1988. 1 indexed citations
4.
Katsuya, Hiroo, Hideaki Nakamura, Hidekazu Itamura, et al.. (2023). HTLV‐1 cell‐free DNA in plasma as a potential biomarker in HTLV‐1 carriers and adult T‐cell leukemia‐lymphoma. SHILAP Revista de lepidopterología. 4(3). 733–737. 3 indexed citations
5.
Ureshino, Hiroshi, Sho Okamoto, Hidekazu Itamura, et al.. (2022). Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. Hematology. 27(1). 1171–1175. 3 indexed citations
6.
Itamura, Hidekazu, Takero Shindo, Kazutaka Kitaura, et al.. (2021). Pharmacological MEK inhibition promotes polyclonal T-cell reconstitution and suppresses xenogeneic GVHD. Cellular Immunology. 367. 104410–104410. 4 indexed citations
7.
Itamura, Hidekazu, Takero Shindo, Satoshi Yoshioka, Takayuki Ishikawa, & Shinya Kimura. (2020). Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation. Blood Advances. 4(4). 667–671. 5 indexed citations
8.
Ureshino, Hiroshi, Takero Shindo, Yasushi Kubota, et al.. (2019). Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation. International Journal of Hematology. 111(5). 733–738. 7 indexed citations
9.
Okamoto, Sho, Hiroshi Ureshino, Hidekazu Itamura, et al.. (2019). Clinical impact of the CONUT score in patients with multiple myeloma. Annals of Hematology. 99(1). 113–119. 39 indexed citations
10.
Itamura, Hidekazu, Takero Shindo, Kazutaka Kitaura, et al.. (2019). The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease. Blood. 134(Supplement_1). 1929–1929. 4 indexed citations
11.
Ureshino, Hiroshi, Hidekazu Itamura, Mariko Yoshimura, et al.. (2018). Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. Annals of Hematology. 98(2). 465–471. 22 indexed citations
12.
Itamura, Hidekazu, Akemi Sato, Naoko Sueoka‐Aragane, et al.. (2018). Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method. International Journal of Hematology. 108(4). 416–422. 2 indexed citations
13.
Itamura, Hidekazu, Yasushi Kubota, Takero Shindo, et al.. (2017). Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg. Clinical Lymphoma Myeloma & Leukemia. 17(6). 370–374. 15 indexed citations
14.
Ureshino, Hiroshi, Toshihiko Ando, Hidekazu Itamura, et al.. (2017). Three coexisting lymphomas in a single patient: composite lymphoma derived from a common germinal center B-cell precursor and unrelated discordant lymphoma. International Journal of Hematology. 107(6). 703–708. 3 indexed citations
15.
Ureshino, Hiroshi, Toshihiko Ando, Hidekazu Itamura, et al.. (2017). Tocilizumab for severe cytokine‐release syndrome after haploidentical donor transplantation in a patient with refractory Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma. Hematological Oncology. 36(1). 324–327. 9 indexed citations
16.
Itamura, Hidekazu, Takero Shindo, Isao Tawara, et al.. (2016). The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects. JCI Insight. 1(10). 22 indexed citations
17.
Fukushima, Noriyasu, Hidekazu Itamura, Hideo Wada, et al.. (2014). A Novel Frameshift Mutation in Exon 4 Causing a Deficiency of High-molecular-weight Kininogen in a Patient with Splenic Infarction. Internal Medicine. 53(3). 253–257. 5 indexed citations
18.
Sueoka, Eisaburo, Yasushi Kubota, Hidekazu Itamura, et al.. (2013). MANAGEMENT OF TRANSFUSIONAL IRON OVERLOAD. Japanese Journal of Transfusion and Cell Therapy. 59(1). 73–78. 1 indexed citations
19.
Ogata, Masao, Takako Satou, Jun‐ichi Kadota, et al.. (2013). Human Herpesvirus 6 (HHV-6) Reactivation and HHV-6 Encephalitis After Allogeneic Hematopoietic Cell Transplantation: A Multicenter, Prospective Study. Clinical Infectious Diseases. 57(5). 671–681. 129 indexed citations
20.
Tanaka, Mariko, Noriyasu Fukushima, Hidekazu Itamura, et al.. (2009). Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia. International Journal of Hematology. 91(1). 132–135. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniela Vallerini Breakdown of academic impact, for papers by Ryoko Yamasaki Breakdown of academic impact, for papers by Maite Encuentra Breakdown of academic impact, for papers by Evren Özdemir Breakdown of academic impact, for papers by Yuichiro Nawa Breakdown of academic impact, for papers by D I Marks Breakdown of academic impact, for papers by Chiara Quadrelli Breakdown of academic impact, for papers by Irene García‐Cadenas Breakdown of academic impact, for papers by Joanne Filicko-O’Hara Breakdown of academic impact, for papers by Erik L. Kimble
Rankless by CCL
2026